G1 EXECUTION SERVICES, LLC 4
4 · ACHILLION PHARMACEUTICALS INC · Filed Jan 30, 2020
Insider Transaction Report
Form 4
G1 EXECUTION SERVICES, LLC
10% Owner
Transactions
- Other
Common Stock
2020-01-28$6.30/sh−14,115,498$88,927,637→ 0 total - Other
Common Stock
2020-01-28$6.30/sh−10,917$68,777→ 0 total
Footnotes (4)
- [F1]Disposed of pursuant to an Agreement and Plan of Merger among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
- [F2]These securities are directly owned by G1 Execution Services, LLC ("G1X").
- [F3]These securities are directly owned by Susquehanna Securities, LLC ("SS").
- [F4]G1X, Susquehanna Fundamental Investments, LLC ("SFNDI") and SS are affiliated entities under common ownership. G1X, SFNDI and SS each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that any of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.